MetaCap

CVRx (CVRX) vs Femasys (FEMY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Femasys (FEMY) has outperformed CVRx (CVRX) over the past year, losing 93.3% versus a loss of 94.9%. Over five years, CVRX leads with a -96.1% price change compared with -98.6% for FEMY. CVRx is the larger company by market cap ($14.3 million vs $10.7 million), about 1.3 times the size, while Femasys is growing revenue faster (+40.8% vs +10.4%).

CVRx converts more of its revenue into profit, with a net margin of -94.1% versus -812.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CVRX-94.91%FEMY-93.26%
+15%-43%-100%
Nov 21, 20251 yearNov 20, 2026
CVRX-96.21%FEMY-98.76%
+150%+20%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CVRX versus FEMY key metrics
MetricCVRXFEMY
Share price$0.501$1.24
Market cap$14.27M$10.73M
1-day change-5.99%0.00%
YTD return-92.94%-89.24%
1-year return-94.91%-93.26%
5-year return-96.13%-98.63%
EPS (TTM)$-2.00$-1.79
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$56.65M$2.29M
Revenue growth (YoY)+10.45%+40.77%
Net income (latest FY)$-53.31M$-18.63M
Gross margin85.33%61.96%
Operating margin-90.49%-766.95%
Net margin-94.10%-812.27%
52-week high$10.28$20.80
52-week low$0.497$1.07
Distance from 52-week high-95.13%-94.04%
Analyst consensusnonenone
Avg. price target upside+814.17%+1055.65%
Average volume744.45K110.75K
Shares outstanding28.49M8.66M
Employees22351
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CVRx is more profitable, keeping -94.1 cents of every revenue dollar as net income versus -812.3 cents for Femasys.
  • Femasys grew revenue faster in its latest fiscal year (+40.77% vs +10.45%).

About CVRx

CVRX stock →

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system.

Health Care · Medical/Dental Instruments · 223 employees

About Femasys

FEMY stock →

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation.

Health Care · Medical/Dental Instruments · 51 employees

CVRX vs FEMY FAQ

Which is bigger, CVRx or Femasys?

CVRx (CVRX) is larger, with a market capitalization of $14.27M compared with $10.73M for Femasys (FEMY).

Which stock has performed better over the past year, CVRX or FEMY?

FEMY returned -93.26% over the past 12 months, compared with -94.91% for CVRX (price return, excluding dividends). Past performance does not predict future results.

Are CVRx and Femasys in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons